In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented key findings from the DELTA 3 trial at the prestigious 82nd American Academy of Dermatology (AAD) Congress in San Diego, California. This marks the first public disclosure of the results from the trial, underscoring the company’s innovative strides with delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor, targeting chronic hand eczema.

The DELTA 3 trial, an extension of the prior DELTA 1 and DELTA 2 studies, focused on the long-term safety and efficacy of as-needed delgocitinib cream application over 36 weeks. Participants from the initial trials who completed a 16-week treatment period were eligible for DELTA 3, where the cream was used as needed to manage symptoms. The primary endpoint of this trial confirmed the continuity of a reassuring safety profile, with no new safety concerns arising. The most commonly reported treatment-emergent adverse events included COVID-19 and nasopharyngitis.

Kreesten Meldgaard Madsen, Chief Development Officer at LEO Pharma, reflected on the significance of these findings: “This late-breaker presentation marks a proud moment in our journey to support the critical unmet need in chronic hand eczema. Having the opportunity to present the DELTA 3 findings for the first time at AAD is a chance to prove our complete dedication to addressing the immense burden of this disease.”

The DELTA 3 trial results offered a glimpse of hope for adults grappling with chronic hand eczema, a condition historically limited in treatment options. Dr. Melinda Gooderham, Lead Author and Medical Director at the SKiN Centre for Dermatology, underscored the impact of these findings, stating, “The results from DELTA 3 offer hope to adults living with chronic hand eczema, a patient group who have been left to deal with their debilitating condition with minimal treatment options.”

Additional data sets from the preceding DELTA 1 and 2 trials were also shared as e-posters at the AAD meeting, encompassing safety, efficacy, and systemic exposure insights.

The DELTA 3 trial results presented by LEO Pharma A/S at the AAD Congress represent a pivotal advancement in the treatment of chronic hand eczema. The consistent safety profile and improved efficacy outcomes highlight the potential of delgocitinib cream as a promising new therapy option. This research exemplifies the significant strides being made in dermatological science, offering renewed hope and enhanced treatment strategies for those afflicted by this challenging condition.

  American Academy of Dermatology, chronic hand eczema, Delgocitinib Cream, DELTA 3 Trial, Dermatology Innovation, JAK-Inhibitor, LEO Pharma